About Rivus Pharmaceuticals

Rivus Pharmaceuticals develops Controlled Metabolic Accelerators (CMAs), oral small molecules that utilize mitochondrial uncoupling to enhance fat oxidation and improve cellular metabolism. Their lead candidate, HU6, targets obesity and related cardiometabolic diseases by promoting fat-specific weight loss while preserving muscle mass and improving key metabolic parameters.

```xml <problem> Obesity and related cardiometabolic diseases, such as heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD), and type 2 diabetes, are driven by excess fat accumulation. Current weight loss therapies may also reduce lean muscle mass, potentially leading to weight regain and increased cardiovascular risk. </problem> <solution> Rivus Pharmaceuticals develops Controlled Metabolic Accelerators (CMAs), oral small molecules designed to reduce excess fat and treat a range of cardiometabolic diseases. CMAs safely leverage mitochondrial uncoupling, a natural metabolic process, to promote fat-specific weight loss while preserving muscle mass. By increasing the breakdown of fats and sugars and increasing resting energy expenditure, CMAs improve cellular metabolism and address the underlying cause of cardiometabolic diseases. Rivus' lead CMA candidate, HU6, is currently in clinical development for obesity and associated cardiometabolic diseases. </solution> <features> - Oral, small molecule therapies designed to improve cellular metabolism - Harnesses mitochondrial uncoupling to increase fat oxidation and energy expenditure - Promotes fat-specific weight loss while preserving skeletal muscle mass - Reduces liver and visceral fat - Improves glycemic control and reduces inflammation - HU6, a first-in-class CMA, has demonstrated improvements in disease markers of blood pressure, inflammation, and glycemic control in Phase 2 clinical trials - Pipeline includes additional CMA candidates for preclinical development - AI/ML classifier model trained on proprietary datasets to identify new CMA candidates </features> <target_audience> The primary target audience includes patients with obesity and related cardiometabolic diseases such as heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD) / metabolic dysfunction-associated steatohepatitis (MASH) and Type 2 diabetes, as well as physicians and healthcare providers treating these conditions. </target_audience> ```

What does Rivus Pharmaceuticals do?

Where is Rivus Pharmaceuticals located?

Rivus Pharmaceuticals is based in Charlottesville, United States.

When was Rivus Pharmaceuticals founded?

Rivus Pharmaceuticals was founded in 2019.

How much funding has Rivus Pharmaceuticals raised?

Rivus Pharmaceuticals has raised 223980000.

Location

Charlottesville, United States

Founded

2019

Funding

223980000

Employees

19 employees

Major Investors

RA Capital Management

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Rivus Pharmaceuticals

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

rivuspharma.com 3K+

Crunchbase

Founded 2019 – Charlottesville, United States

Funding

Estimated Funding

$200M+

Major Investors

RA Capital Management

Team (15+)

No team information available.

Company Description

Problem

Obesity and related cardiometabolic diseases, such as heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD), and type 2 diabetes, are driven by excess fat accumulation. Current weight loss therapies may also reduce lean muscle mass, potentially leading to weight regain and increased cardiovascular risk.

Solution

Rivus Pharmaceuticals develops Controlled Metabolic Accelerators (CMAs), oral small molecules designed to reduce excess fat and treat a range of cardiometabolic diseases. CMAs safely leverage mitochondrial uncoupling, a natural metabolic process, to promote fat-specific weight loss while preserving muscle mass. By increasing the breakdown of fats and sugars and increasing resting energy expenditure, CMAs improve cellular metabolism and address the underlying cause of cardiometabolic diseases. Rivus' lead CMA candidate, HU6, is currently in clinical development for obesity and associated cardiometabolic diseases.

Features

Oral, small molecule therapies designed to improve cellular metabolism

Harnesses mitochondrial uncoupling to increase fat oxidation and energy expenditure

Promotes fat-specific weight loss while preserving skeletal muscle mass

Reduces liver and visceral fat

Improves glycemic control and reduces inflammation

HU6, a first-in-class CMA, has demonstrated improvements in disease markers of blood pressure, inflammation, and glycemic control in Phase 2 clinical trials

Pipeline includes additional CMA candidates for preclinical development

AI/ML classifier model trained on proprietary datasets to identify new CMA candidates

Target Audience

The primary target audience includes patients with obesity and related cardiometabolic diseases such as heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD) / metabolic dysfunction-associated steatohepatitis (MASH) and Type 2 diabetes, as well as physicians and healthcare providers treating these conditions.